Monday, July 27, 2026

In case you

missed it ...

July 24, 2026

Pharma Looks to Cash in on Psychedelics as Patients Seek Alternatives to Psychotropic Drugs for Depression

Eli Lilly’s multibillion-dollar acquisition of a company that makes experimental psychedelic therapies marks the largest investment yet by a drugmaker in psychedelic medicine as a treatment for depression. But pharma’s entry into the market raises questions about patents, profits and the future of psychedelic therapy.

Now you can bookmark your favorite Defender articles to read them later.

Not a CHD Insider yet? Join today with a small monthly donation to make a big impact.

Support news that prioritizes

your children's well-being

Children's Health Defense® is a 501(c)(3) non-profit organization. Our mission is ending childhood health epidemics by eliminating toxic exposure. We will restore and protect the health of children by eliminating environmental exposures, holding responsible parties accountable, and establishing safeguards to prevent future harm of children's health. Protecting Children. Exposing Harms. Seeking Justice.

Children's Health Defense